Literature DB >> 19240609

Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.

Benoit J M Pirotte1, Marc Levivier, Serge Goldman, Nicolas Massager, David Wikler, Olivier Dewitte, Michael Bruneau, Sandrine Rorive, Philippe David, Jacques Brotchi.   

Abstract

OBJECTIVE: Integrating positron emission tomographic (PET) images into the image-guided resection of high-grade gliomas (HGG) has shown that metabolic information on tumor heterogeneity and distribution are useful for planning surgery, improve tumor delineation, and provide a final target contour different from that obtained with magnetic resonance imaging (MRI) alone in about 80% of the procedures. Moreover, PET guidance helps to increase the amount of tumor removed and to target image-guided resection to anaplastic tissue areas. The present study aims to evaluate whether PET-guided volumetric resection (VR) in supratentorial HGG might add benefit to the patient's outcome.
METHODS: PET images using [18F]fluorodeoxyglucose (n=23) and [11C]methionine (n=43) were combined with MRI scans in the planning of VR procedures performed at the initial stage in 66 consecutive patients (43 M/23 F) with supratentorial HGG according to the technique previously described. In all cases (35 anaplastic gliomas [20 astrocytomas, 10 oligoastrocytomas, 5 oligodendrogliomas] and 31 glioblastomas [GBM]), level and distribution of PET tracer uptake were analyzed to define a PET contour projected on MRI scans to define a final target contour for VR. Maximal tumor resection was accomplished in each case, with the intention to remove the entire abnormal metabolic area comprised in the surgical planning. Early postoperative MRI and PET assessed tumor resection. Survival analysis was performed separately in anaplastic gliomas and glioblastoma multiforme according to the presence or absence of residual tracer uptake on postoperative PET and according to the presence or absence of residual contrast enhancement on postoperative MRI.
RESULTS: Preoperatively, metabolic information helped the surgical planning. In all procedures, PET contributed to define a final target contour different from that obtained with MRI alone. Postoperatively, 46 of 66 patients had no residual PET tracer uptake (total PET resection), 23 of 66 had no residual MRI contrast enhancement. No additional neurological morbidity due to the technique was reported. A total PET tracer uptake resection was associated with a significantly longer survival in anaplastic gliomas (P = 0.0071) and in glioblastoma multiforme (P = 0.0001), respectively. A total MRI contrast enhancement resection was not correlated with a significantly better survival, neither in anaplastic gliomas (P = 0.6089) nor in glioblastoma multiforme (P = 0.6806).
CONCLUSIONS: Complete resection of the increased PET tracer uptake prolongs the survival of HGG patients. Because PET information represents a more specific marker than MRI enhancement for detecting anaplastic tumor tissue, PET-guidance increases the amount of anaplastic tissue removed in HGG.

Entities:  

Mesh:

Year:  2009        PMID: 19240609     DOI: 10.1227/01.NEU.0000338949.94496.85

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  52 in total

Review 1.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

2.  A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.

Authors:  Makoto Ideguchi; Takafumi Nishizaki; Norio Ikeda; Tomomi Okamura; Yasue Tanaka; Natsumi Fujii; Machiko Ohno; Taichi Shimabukuro; Tokuhiro Kimura; Eiji Ikeda; Kazuyoshi Suga
Journal:  J Neurooncol       Date:  2018-03-07       Impact factor: 4.130

Review 3.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

4.  Upfront chemotherapy and subsequent resection for molecularly defined gliomas.

Authors:  Hikaru Sasaki; Yuichi Hirose; Takahito Yazaki; Yohei Kitamura; Makoto Katayama; Tokuhiro Kimura; Hirokazu Fujiwara; Masahiro Toda; Takayuki Ohira; Kazunari Yoshida
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

Review 5.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

6.  MRI findings and pathological features in early-stage glioblastoma.

Authors:  Makoto Ideguchi; Koji Kajiwara; Hisaharu Goto; Kazutaka Sugimoto; Sadahiro Nomura; Eiji Ikeda; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

Review 7.  Current status and future role of brain PET/MRI in clinical and research settings.

Authors:  P Werner; H Barthel; A Drzezga; O Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

8.  Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.

Authors:  Kevin Petrecca; Marie-Christine Guiot; Valerie Panet-Raymond; Luis Souhami
Journal:  J Neurooncol       Date:  2012-10-10       Impact factor: 4.130

Review 9.  Technical principles in glioma surgery and preoperative considerations.

Authors:  Daria Krivosheya; Sujit S Prabhu; Jeffrey S Weinberg; Raymond Sawaya
Journal:  J Neurooncol       Date:  2016-06-17       Impact factor: 4.130

10.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.